


ED Guideline on Outpatient COVID-19 Treatment



Write prescription to pharmacy with medication available per the locator (recommend pharmacist consult)²:

PaxlovidTM (nirmatrelvir 300 mg; ritonavir 100 mg) twice daily for 5 days (Nirmatrelvir 150 mg for eGFR \geq 30 to <60 mL/min)

Give patient Fact Sheet for Patients, Parents, and Caregivers

- 1. Given resource limitations, consideration for MAB use should be reserved for patients at the highest risk for severe COVID (immunocompromised individuals, unvaccinated persons who have multiple comorbidities or are pregnant etc.). Approval will be given on a case-by-case based on individual patient and available supply.
- 2. Pharmacist consult recommended for Paxlovid to assess drug interactions, contraindications, and dose adjustments. Tiger Text ED Pharmacist or UH ASP. If a clinical pharmacist is not available, call main pharmacy 2-5123.



ED Guideline on Outpatient COVID-19 Treatment

PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets): FULL FACT SHEET FOR HEALTHCARE PROVIDERS

Mechanism of Action: Nirmatrelvir is a SARS-CoV-2 main protease (Mpro) inhibitor and ritonavir is an HIV-protease inhibitor and CYP3A inhibitor

Dosage: 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) twice daily for 5 days

Indication

- Indicated for treatment of mild-to-moderate COVID-19 in adult and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death within 5 days of symptom onset
 - Under emergency use authorization (EUA). Give Fact Sheet for Patients, Parents and Caregivers

Warnings and Contraindications

- Requires dose adjustment in renal disease. Contraindicated in severe renal and hepatic impairment (refer to fact sheet or call pharmacist)
- MANY CLINICALLY SIGNIFICANT DRUG-DRUG INTERACTIONS, including potentially life-threating interactions
 - o Summary of interactions with common medications. THIS IS NOT A COMPREHENSIVE LIST. Use https://www.covid19-druginteractions.org/checker to confirm all interactions

- No safety data in pregnancy. Consult ASP/ID

Drug Class	Drugs within Class	Clinical Comments
Antianginal	Ranolazine	Contraindicated due to potential for life-threatening reactions
Antiarrhythmics	Amiodarone,	Contraindicated due to potential for cardiac arrhythmias
	dronedarone, flecainide,	
	propafenone, quinidine	
Anticancer drugs	Many	Many contraindicated or not recommended due to side effects.
		Check for interactions if patient is on any cancer therapy
Anticoagulants	Warfarin	Closely monitor INR if co-administration with warfarin is
		necessary
	B: 1	
	Rivaroxaban	Increased bleeding risk with rivaroxaban. Avoid concomitant use.
Anticonvulsants	Carbamazepine,	Contraindicated due to potential loss of virologic response and
	phenobarbital, phenytoin	possible resistance
Antigout	Colchicine	Contraindicated due to potential for life-threatening reactions
Antipsychotics	Lurasidone, pimozide,	Contraindicated due to potential for cardiac arrhythmias
	clozapine	
Calcium channel	Amlodipine, diltiazem,	Dose decrease may be needed when co-administered
blockers	nicardipine, nifedipine	
HMG-CoA reductase	Lovastatin, simvastatin	Contraindicated due to potential or myopathy including
inhibitors		rhabdomyolysis
	Atorvastatin, rosuvastatin	Consider temporary discontinuation during treatment
Hormonal	Ethinyl estradiol	An additional, non-hormonal method of contraception should be
contraceptive		considered
Immunosuppressants	Cyclosporine, tacrolimus,	Not recommended due to effect on immunosuppressant levels.
	sirolimus	Consider monoclonals.
Opioid analgesic	Fentanyl	Increased fentanyl effects. Careful monitoring of adverse events
		(including fatal respiratory depression) recommended



BEBTELOVIMAB FULL FACT SHEET FOR HEALTHCARE PROVIDERS

Mechanism of Action: Bebtelovimab is a recombinant neutralizing human $lgG1_{\lambda}$ monoclonal antibody to the spike protein of SARS-CoV-2 and is unmodified in the Fc region.

Dosage: 175 mg administered as a single intravenous injection over at least 30 seconds

Indication

- Indicated for treatment of mild-to-moderate COVID-19 in adult and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death within 7 days of symptom onset
 - Current under emergency use authorization (EUA). Give patient <u>Fact Sheet for Patients</u>, <u>Parents</u> and <u>Caregivers</u>
- No dose adjustments or clinically significant drug-drug interactions

Monitoring

- Clinically monitor patients for possible infusion-related reactions during administration and observe patients for at least 1 hour after injection is complete